SS-31 (Elamipretide)
SS-31, also known as elamipretide, is a mitochondria-targeting peptide used for cellular energy support, exercise recovery, and anti-aging. It's the first and only approved therapy for Barth syndrome, a rare mitochondrial muscle disorder, and it works by binding a key molecule in the mitochondrial membrane to help cells produce energy more efficiently. It's marketed more broadly for energy, exercise recovery, and healthy aging as part of mitochondrial-support protocols.
$175 / 50 mg vial
Dosing
Community reported
| Timeframe | Dosage | Frequency | Note |
|---|---|---|---|
| Weeks 1-2 | 5 mg | once daily | Starting dose |
| Weeks 3-8 | 10 mg | once daily | Maintenance1 |
- peptidedosages.com's own standard-approach schedule, distinct from the FDA-approved Barth syndrome dose and the other trial doses in Full research; not derived from a controlled human dose-ranging trial of this specific titration.
Community reported
| Timeframe | Dosage | Frequency | Note |
|---|---|---|---|
| Weeks 1-2 | 5 mg | once daily | |
| Weeks 3-4 | 10 mg | once daily | |
| Weeks 5-8 | 15 mg | once daily, split 2x | 1 |
| Weeks 9-12 | 20 mg | once daily, split 2x | Optional, site's max2 |
- Framed by the site under a medical-supervision caveat; split into two injections at this dose level.
- The site's stated maximum for this optional advanced phase; not derived from a controlled human dose-ranging trial of this titration.
Batches on hand
Availability
30 vials on hand.
MKM-2S50-26072630 vials
Full research
Evidence tier
Barth syndrome (FDA-approved indication): Approved drug, human RCT evidenceGeneral and off-label use (mitochondrial myopathy, heart failure, dry AMD, acute MI, and community anti-aging or wellness use): Human trials, not approved for this use
Barth syndrome (FDA-approved indication): FDA granted accelerated approval to elamipretide (Forzinity) for Barth syndrome in September 2025, so it meets the letter of this top tier. But the approval is built on a secondary and intermediate endpoint (knee extensor muscle strength) observed mainly during an open-label extension, reached only after the pivotal TAZPOWER trial's own co-primary endpoints (6-minute walk distance and fatigue score) were not met in the randomized phase, after a Complete Response Letter tied to a third-party manufacturing-facility inspection finding, and after a split 10-6 FDA advisory committee vote on efficacy. Continued approval for this indication is explicitly contingent on FDA's review of a confirmatory trial. This is genuine, regulator-reviewed human evidence, but for a single narrow indication in a specific rare genetic disease, not a broad efficacy finding, and it does not extend to any other use of the compound.
General and off-label use (mitochondrial myopathy, heart failure, dry AMD, acute MI, and community anti-aging or wellness use): This tier label, by itself, only tells a reader that human trials exist and no approval followed, which understates what actually happened here: completed, randomized, controlled trials were run for primary mitochondrial myopathy (MMPOWER-3), heart failure with reduced ejection fraction (PROGRESS-HF), dry age-related macular degeneration (ReCLAIM-2), and acute MI ischemia-reperfusion injury (EMBRACE-STEMI), and every one of them missed its own pre-specified primary endpoint. These are negative trials, not merely not-yet-approved trials, and the same compound's narrow success in Barth syndrome (see the other tier variant) does not transfer to any of these broader uses, which is exactly how the compound is actually marketed and sold in the community and wellness market today. Secondary and post hoc findings exist in several of these trials (a nuclear-DNA-variant subgroup signal in MMPOWER-3, ellipsoid-zone and low-luminance visual acuity secondary endpoints in ReCLAIM-2, a biomarker reduction in EMBRACE-STEMI's HtrA2 substudy), but none rises to a primary-endpoint success. A rodent HFpEF model similarly found mitochondrial biomarker improvement without functional cardiac benefit, the same gap illustrated at the preclinical level.
Original dosing schedule
The Dosing table above this section now shows a community- or vendor-sourced schedule (peptidedosages.com). The regulatory-label or clinical-trial dosing this entry was originally built on is kept here, unchanged, rather than removed.
Clinical trial
| Timeframe | Dosage | Frequency | Note |
|---|---|---|---|
| Ongoing | 40 mg | once daily | 12 |
- Randomized, double-blind, placebo-controlled crossover (two 12-week periods separated by a 4-week washout), followed by an open-label extension of up to 192 weeks. Under the FDA-approved label for this indication, severe renal impairment (eGFR under 30 mL/min, not on dialysis) reduces the dose to 20 mg once daily; no adjustment is needed for mild or moderate impairment.
- Vendor and wellness-clinic marketing describes a wide, inconsistent range from roughly 250-500 mcg/day up to 5-20 mg/day, and in some cases up to 40 mg/day borrowed directly from this trial dose; none of these general-wellness amounts has been studied in a published human trial.
Clinical trial
| Timeframe | Dosage | Frequency | Note |
|---|---|---|---|
| 24-week trial | 40 mg | once daily |
Clinical trial
| Timeframe | Dosage | Frequency | Note |
|---|---|---|---|
| 28-day trial | 4 mg or 40 mg | once daily | Trial arms1 |
- Trial arms were placebo, 4 mg, or 40 mg once daily for 28 days; not a titration.
Clinical trial
| Timeframe | Dosage | Frequency | Note |
|---|---|---|---|
| 48-week trial | 40 mg | once daily |
EMBRACE-STEMI, acute MI (intravenous) – No citable dose
No citable figure. This research did not confirm the specific milligram or weight-based intravenous dose used in the EMBRACE-STEMI pivotal publication. Do not treat any specific EMBRACE-STEMI IV dose figure found elsewhere as confirmed without checking the primary trial registration (NCT01572909) or publication directly.
Identity
| Full name | Elamipretide (International Nonproprietary Name), most commonly known in research and commercial contexts as SS-31, carried through earlier development under the code names MTP-131 and Bendavia. The FDA-approved product is branded FORZINITY (elamipretide hydrochloride injection). |
|---|---|
| Class | Synthetic, cell-permeable, mitochondria-targeting aromatic-cationic tetrapeptide. The FDA label's own functional class term is mitochondrial cardiolipin binder. |
| Brand names | FORZINITY |
| Molecular weight | 749.2 g/mol |
| Sequence | D-Arg-2,6-dimethyl-Tyr-Lys-Phe-NH2 (D-arginine, 2,6-dimethyl-L-tyrosine, L-lysine, L-phenylalaninamide; all residues L-configured except the D-configured arginine). Hydrochloride salt chemical name: L-Phenylalaninamide, D-arginyl-2,6-dimethyl-L-tyrosyl-L-lysyl-, hydrochloride (1:3). Molecular weight given here (749.2) is for the hydrochloride salt (C32H49N9O5.3HCl) as stated on the FDA label; the free-base peptide typically quoted on vendor chemistry pages works out to approximately 639.8 Da. |
Mechanism of action
Plain language
Elamipretide is built to concentrate specifically inside mitochondria, the cell's energy-generating structures, and to stick to a fat molecule called cardiolipin that sits in the mitochondria's inner membrane. Cardiolipin's shape and chemistry help organize the membrane machinery that produces the cell's chemical energy currency, ATP. The premise is that by binding cardiolipin and stabilizing that membrane architecture, elamipretide helps damaged or stressed mitochondria produce energy more efficiently and leak fewer damaging byproducts.
Technical
Established (FDA label): FORZINITY is a mitochondrial cardiolipin binder that localizes to the inner mitochondrial membrane and improves mitochondrial morphology and function; this one-sentence description is the only mechanism claim FDA required to be supported for approval. Independent biophysical work confirms the compound is cell-permeable, concentrates in the inner mitochondrial membrane independent of membrane potential, and binds cardiolipin through electrostatic and hydrophobic interactions. Proposed, not fully established: cardiolipin binding is hypothesized to stabilize cristae architecture, support electron transport chain supercomplex assembly, and reduce electron leak and reactive oxygen species production, thereby improving coupled ATP synthesis. A 2020 protein-interaction-mapping study found binding partners including ATP synthase and the adenine nucleotide translocase, suggesting effects beyond a narrowly cardiolipin-specific interaction, and a separate biophysical study proposed a more general lipid-bilayer surface-electrostatics mechanism. Review literature as recent as 2025 continues to describe the precise mechanism as not fully elucidated, despite the label's confident one-sentence characterization.
Sources: FDA-approved prescribing information, 2025, The mitochondria-targeted peptide, Mitochondrial protein interaction, 2020, Elamipretide: A Review, 2025, Contemporary insights into, 2025
Why: Approved for Barth syndrome only
FDA granted accelerated approval to elamipretide (Forzinity) in September 2025 for exactly one indication: improving muscle strength in Barth syndrome patients weighing at least 30 kg. This is elamipretide's only approved use anywhere; every other indication tested in a human RCT remains unapproved.
Sources: FDA-approved prescribing information, 2025
Why: A contested approval path
The approval followed a Complete Response Letter tied to a third-party manufacturing-facility inspection finding and a split 10-6 FDA advisory committee vote on efficacy. It rests on a secondary and intermediate endpoint reached mainly during an open-label extension, after the pivotal trial's own co-primary endpoints were not met in the randomized phase. Continued approval is explicitly contingent on a confirmatory trial.
Sources: FDA-approved prescribing information, 2025, FDA Cardiovascular and, 2024, FierceBiotech, FiercePharma, Cardiology
Why: Biomarker gains without functional benefit
A rodent heart-failure-with-preserved-ejection-fraction model found elamipretide improved myocardial mitochondrial bioenergetics without translating into functional cardiac benefit, a direct illustration that a mechanistic or biomarker improvement does not guarantee clinical benefit, exactly the gap between elamipretide's mitochondrial mechanism and its largely negative human trial record outside Barth syndrome.
Sources: Mitochondrial Targeting by, 2026
What it’s used for
Approved
- Improving muscle strength in adult and pediatric patients weighing at least 30 kg with Barth syndrome, a rare X-linked recessive disorder caused by TAFAZZIN gene mutations that disrupt cardiolipin remodeling in mitochondrial membranes, under FDA accelerated approval granted September 19, 2025. This is the first and only approved therapy for Barth syndrome, and elamipretide's only approved indication anywhere.
Sources: FDA-approved prescribing information, 2025, Reid Thompson W,, 2021, Long-term efficacy and, 2024, Natural history comparison
Human trials, not approved for this use
- Primary mitochondrial myopathy (a broader, genetically heterogeneous category distinct from Barth syndrome specifically): MMPOWER-3, a phase 3, 24-week, randomized, double-blind, placebo-controlled trial in 218 adults, found no significant difference from placebo on either co-primary endpoint (6-minute walk distance, least-squares mean difference -3.2 m; total fatigue score on the Primary Mitochondrial Myopathy Symptom Assessment, change -0.07). A post hoc analysis found a possible benefit specific to the nuclear-DNA-variant subgroup, with no effect in the mitochondrial-DNA-variant subgroup. An earlier randomized dose-escalation trial in primary mitochondrial myopathy patients established tolerability across a dose range.
Sources: Efficacy and Safety, 2023, Genotype-specific effects of, Randomized dose-escalation trial
- Heart failure with reduced ejection fraction: PROGRESS-HF, a phase 2 trial randomizing 71 patients with LVEF 40% or less to placebo, 4 mg, or 40 mg elamipretide once daily subcutaneously for 28 days, found the drug well tolerated but not associated with improvement in left ventricular end-systolic volume, its primary endpoint. An earlier single-dose ascending IV-infusion study in HFrEF patients evaluated safety and pharmacodynamics. No completed human RCT of elamipretide specifically in heart failure with preserved ejection fraction (HFpEF) was identified; the only HFpEF data found is a rodent study (see the Biomarker gains without functional benefit note below).
Sources: Effects of Elamipretide, 2020, Novel Mitochondria-Targeting Peptide
- Dry age-related macular degeneration with geographic atrophy: ReCLAIM-2, a phase 2, randomized, placebo-controlled, double-masked trial (daily subcutaneous elamipretide 40 mg for 48 weeks), did not meet its primary endpoints of geographic atrophy lesion growth or low-luminance visual acuity change. Secondary findings included a 43 percent reduction in mean progression of ellipsoid zone total attenuation and loss versus placebo (p equals 0.003), and significantly more elamipretide-treated patients gaining 10 or more letters of low-luminance best-corrected visual acuity (14.6 percent versus 2.1 percent on placebo). Two phase 3 trials (ReNEW, ReGAIN) were still underway as of mid-2026, with no topline results reported.
Sources: ReCLAIM-2: A Randomized, 2024
- Acute ST-elevation myocardial infarction and ischemia-reperfusion injury: EMBRACE-STEMI, a phase 2a randomized, double-blind, placebo-controlled trial of intravenous elamipretide given before percutaneous coronary intervention, did not reduce infarct size on its primary endpoint (area under the curve of CK-MB), though the drug was reported safe and well tolerated. A substudy found elamipretide reduced circulating HtrA2, a mitochondrial stress biomarker, without establishing clinical benefit. A separate phase 2a trial evaluated elamipretide during stent revascularization for atherosclerotic renal artery stenosis; this research did not confirm a specific efficacy result for that trial and does not assert one. Broader ischemia-reperfusion protection in rodent models underlies the rationale for both of these human trials.
Sources: Gibson CM, et, 2016, The mitochondria-targeting peptide, Phase 2a Clinical, Therapeutic Peptides to
- A single-dose randomized trial in older but otherwise healthy adults found improved in vivo mitochondrial ATP production in skeletal muscle after one dose of elamipretide, a mechanistic and pharmacodynamic finding rather than a clinical efficacy result.
Sources: In vivo mitochondrial
Off-label / community use
- SS-31 is widely sold and marketed in the peptide-retail and longevity-clinic community for anti-aging, energy, exercise recovery, cognitive vitality, and general mitochondrial support, framing that draws on the compound's mitochondrial mechanism, its narrow Barth syndrome approval, and preclinical aging and longevity literature, none of which constitutes human efficacy evidence for these general-wellness uses at the doses commonly sold.
Sources: Aggregated commercial vendor, Long-term treatment with, Elamipretide (SS-31) Treatment
Pharmacokinetics
| Time to peak plasma concentration (Tmax) |
Regulatory label 0.5 to 1 hour after subcutaneous injection |
|---|---|
| Absolute bioavailability, subcutaneous route |
Regulatory label Approximately 92 percent; exposure is comparable whether injected into the thigh or the abdomen |
| Dose proportionality |
Regulatory label Exposure increases proportionally across the 2 to 80 mg subcutaneous dose range studied, with minimal accumulation on daily dosing |
| Volume of distribution |
Regulatory label Approximately 0.5 L/kg, consistent with distribution through total body water |
| Plasma protein binding |
Regulatory label Low, approximately 39 percent |
| Metabolism |
Regulatory label Sequential C-terminal degradation to an inactive M1 tripeptide and M2 dipeptide metabolite; no hepatic metabolism observed in vitro, and hepatic impairment is not expected to alter elamipretide pharmacokinetics |
| Excretion |
Regulatory label Renal. Approximately 100 percent of an administered dose is recovered in urine (as parent drug plus M1 and M2 metabolites) by 48 hours post-dose in patients with normal renal function |
| Elimination half-life |
Not established No citable figure. The FDA label's clinical pharmacology section does not state an explicit elimination half-life figure; it characterizes absorption (Tmax) and near-complete urinary recovery by 48 hours but stops short of a labeled t1/2 value. Secondary sources aggregated during the underlying research describe an elimination half-life of approximately 3 to 4 hours after subcutaneous administration, but that specific figure could not be directly verified against the primary FDA label text, which conspicuously omits it. Treat any specific half-life number for elamipretide as unconfirmed against the primary source until checked directly. |
| Renal impairment effect on exposure |
Regulatory label AUC increased 39 percent at creatinine clearance 60-89 mL/min, 75 percent at 30-59 mL/min, and 125 percent at under 30 mL/min (not on dialysis); exposure of the inactive M1 and M2 metabolites rose far more steeply, up to 280 percent and 640 percent respectively at severe impairment, the basis for the halved dose in that population. Not studied in patients with renal failure on dialysis. |
| Drug interactions |
Regulatory label Does not inhibit or induce the major CYP enzymes tested (1A, 2D6, 2E1, 2B6, 2C8, 2C9, 2C19, 3A) and does not inhibit most transporters tested (OCT2, BCRP, OAT1, OAT3, OATP1B1, OATP1B3, P-gp, MATE2-K), but is an in vitro inhibitor of MATE1 (IC50 3.53 micromolar). Dedicated IV coadministration studies found no clinically significant PK or pharmacodynamic interaction with aspirin, clopidogrel, or unfractionated heparin. |
Reconstitution
| Vial strength | Commercially sold research-chemical vials, commonly 10 mg or 50 mg lyophilized powder; the owner's inventory is the 50 mg size. This is distinct from the FDA-approved FORZINITY product, which ships as a ready-to-use liquid at 80 mg/mL and never requires reconstitution. |
|---|---|
| Diluent | Bacteriostatic water |
| Diluent volume | 1 mL or 2 mL for a 50 mg vial, per vendor convention |
| Concentration | 50 mg vial with 1 mL yields 50 mg/mL, close to FORZINITY's own approved 80 mg/mL concentration. With 2 mL it yields 25 mg/mL. |
Worked example
Reconstituted with 1 mL bacteriostatic water: 50 mg divided by 1 mL equals 50 mg/mL. A 40 mg dose (the FDA-labeled Barth syndrome dose) equals 40 mg divided by 50 mg/mL, or 0.8 mL, or 80 units on a U-100 insulin syringe. Reconstituted with 2 mL instead: 50 mg divided by 2 mL equals 25 mg/mL; the same 40 mg dose becomes 1.6 mL, or 160 units, which exceeds a standard U-100 syringe's 100-unit (1 mL) single-draw capacity, illustrating why a more concentrated reconstitution is needed to approximate the label-range dose from a 50 mg vial in one injection. For low-end vendor and community wellness dosing, for example 0.5 mg: at 50 mg/mL, 0.5 mg equals 0.01 mL, or 1 unit; at 25 mg/mL, 0.5 mg equals 0.02 mL, or 2 units, roughly two orders of magnitude below the FDA-approved 40 mg Barth syndrome dose. This arithmetic is a unit-conversion reference only; it does not validate off-label reconstitution or use of a research-labeled product this way.
Sources: Aggregated commercial vendor, FDA-approved prescribing information, 2025
Dose calculator
Enter a vial strength, diluent volume, and desired dose to see the resulting concentration, dose volume, and units on a standard U-100 insulin syringe. Nothing entered here is saved, stored, or sent anywhere – the calculation runs only in your browser.
Enable JavaScript to use the interactive calculator. The worked example above already shows a complete calculation for this compound.
Storage and post-reconstitution stability
Unopened storage
Vendor sources commonly describe unreconstituted lyophilized powder as stable refrigerated (2-8 C) for 12 to 24 months, or at room temperature for shipping-scale durations of weeks; this is a commercial claim, not corroborated by a pharmacopeial or clinical source. The FDA-approved FORZINITY product, a different ready-to-use liquid formulation, is labeled to store refrigerated at 2-8 C and never frozen.
Post-reconstitution stability – Vendor claim
Vendor sources describe reconstituted, bacteriostatic-water solution as stable refrigerated for up to approximately 28 days. Refrigerated, 2-8 C. Vendor claim for the lyophilized research-chemical vial, not the FDA-approved product.
Sources: Aggregated commercial vendor, FDA-approved prescribing information, 2025
No citable figure. This 28-day figure is a commercial claim only; it was not corroborated against any pharmacopeial or clinical source in the underlying research, and it should not be treated as equivalent to, or as validating, FORZINITY's own regulator-reviewed instruction to discard an opened vial 8 days after first opening, since the two products are materially different formulations: a preservative-free lyophilized powder requiring user reconstitution versus a benzyl-alcohol-preserved, ready-to-use solution.
Safety
Contraindications
- Serious hypersensitivity to elamipretide or to any FORZINITY excipient.
Notable risks
- Benzyl alcohol toxicity in neonates: FORZINITY is not approved for neonatal or intravenous use. Benzyl-alcohol-containing drugs given intravenously have caused serious, including fatal, reactions in low-birth-weight and preterm neonates, including new-onset or worsening metabolic acidosis progressing to neurotoxicity and, in some cases, gasping syndrome. FORZINITY contains 20 mg/mL of benzyl alcohol; the minimum amount associated with these reactions is not established.
- Serious hypersensitivity reactions requiring emergency intervention have been reported, including skin manifestations (rash, papular lesions, eczematous dermatitis) and respiratory symptoms (cough), with onset ranging from minutes to months after starting treatment. Patients experiencing a serious hypersensitivity reaction should not be rechallenged.
- In the pivotal Barth syndrome safety population (n=12 on elamipretide, n=12 on placebo, crossover design), the most common adverse reactions were injection site reactions: any local administration reaction occurred in 100 percent of elamipretide periods versus 67 percent of placebo periods. Eosinophilia was noted frequently with 30 or more days of exposure, generally peaking around 90 days, and was not associated with clinical symptoms or other laboratory abnormalities.
- No overdose cases were reported in clinical trials. No clinically significant QTc interval prolongation was observed at 3 times the peak concentration produced by the maximum recommended dose.
- This research did not identify a published serious-adverse-event signal specific to the MMPOWER-3, PROGRESS-HF, or ReCLAIM-2 programs beyond injection site reactions consistent with the class-level pattern described above. Absence of a located signal is not the same as a confirmed absence of one; any specific safety claim for those programs should be checked against the primary trial publications directly before use.
Sources
- FDA-approved prescribing information for FORZINITY (elamipretide hydrochloride injection), Stealth Biotherapeutics Inc., NDA 215244, revised 9/2025, via DailyMed (2025)
- FDA Cardiovascular and Renal Drugs Advisory Committee meeting materials, October 10, 2024 (2024)
- FierceBiotech, FiercePharma, Cardiology Advisor, and Rheumatology Advisor news coverage of the Complete Response Letter, advisory committee vote, and accelerated approval
- Reid Thompson W, Hornby B, Manuel R, et al. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome. Genetics in Medicine (2021)
- Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER. Genetics in Medicine (2024)
- Natural history comparison study to assess the efficacy of elamipretide in patients with Barth syndrome
- Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial. Neurology (2023)
- Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial
- Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy. Neurology
- Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial (2020)
- Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide. Circulation: Heart Failure
- ReCLAIM-2: A Randomized Phase II Clinical Trial Evaluating Elamipretide in Age-related Macular Degeneration, Geographic Atrophy Growth, Visual Function, and Ellipsoid Zone Preservation. Ophthalmology Science (2024)
- Gibson CM, et al. EMBRACE STEMI study: a phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention. European Heart Journal (2016)
- The mitochondria-targeting peptide elamipretide diminishes circulating HtrA2 in ST-segment elevation myocardial infarction
- Phase 2a Clinical Trial of Mitochondrial Protection (Elamipretide) During Stent Revascularization in Patients With Atherosclerotic Renal Artery Stenosis
- ClinicalTrials.gov NCT01572909. Evaluation of Myocardial Effects of MTP-131 for Reducing Reperfusion Injury in Patients With Acute Coronary Events (EMBRACE-STEMI registration)
- In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomized trial
- The mitochondria-targeted peptide SS-31 binds lipid bilayers and modulates surface electrostatics as a key component of its mechanism of action
- Mitochondrial protein interaction landscape of SS-31. PNAS (2020)
- Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential. International Journal of Molecular Sciences (MDPI) (2025)
- Contemporary insights into elamipretide's mitochondrial mechanism of action and therapeutic effects. European Journal of Pharmacology (2025)
- Mitochondrial Targeting by Elamipretide Improves Myocardial Bioenergetics Without Translating into Functional Benefits in HFpEF. International Journal of Molecular Sciences (2026)
- Long-term treatment with Elamipretide enhances healthy aging phenotypes in mice
- Elamipretide (SS-31) Treatment Attenuates Age-Associated Post-Translational Modifications of Heart Proteins (preprint, not peer-reviewed)
- Therapeutic Peptides to Treat Myocardial Ischemia-Reperfusion Injury. Frontiers in Cardiovascular Medicine
- Aggregated commercial vendor sources cited only for commercial vial sizes, reconstitution convention, and community dosing description (for example thepeptidecatalog.com, 99puritypeptides.com, peptidescollective.com, peptide-warehouse.com, 24peptides.com, peptideregenesis.com, nationwidepeptides.com, agerejuvenation.com, peptidesinstitute.org, peptideinitiative.com, peptidedosingprotocols.com, chia.health); not used for efficacy, mechanism, or clinically validated dosing claims
- peptidedosages.com, SS-31 10 mg vial dosage protocol
This is a research and educational reference, not medical advice. Nothing on this site is a recommendation to use any compound.